Botanix Pharmaceuticals Limited (ASX:BOT)
Australia · Delayed Price · Currency is AUD 0.0190
+0.0010 (5.56%)
Oct 1, 2026, 4:10 PM AEST
Botanix Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 33.8 | 5.79 | 2.07 | 3.77 | 2.75 |
| 33.8 | 5.79 | 2.07 | 3.77 | 2.75 | |
Revenue Growth | 483.87% | 179.74% | -45.14% | 36.94% | -60.00% |
Cost of Revenue | 14.35 | 3.77 | 3.65 | 5.73 | 10.29 |
Gross Profit | 19.45 | 2.02 | -1.58 | -1.96 | -7.54 |
Selling, General & Admin | 76.04 | 62.15 | 7.94 | 4.41 | 4.28 |
Other Operating Expenses | - | - | - | 1.13 | 0.89 |
Operating Expenses | 88.76 | 84.93 | 12.41 | 7.17 | 5.65 |
Operating Income | -69.31 | -82.91 | -13.99 | -9.13 | -13.19 |
Interest Expense | -2.84 | -5.37 | -0.01 | -0.08 | -0.04 |
Interest & Investment Income | 1.11 | 1.88 | 0.08 | 0.07 | 0.04 |
Currency Exchange Gain (Loss) | -0.32 | 0.01 | 0.06 | -0.01 | 0.02 |
Other Non Operating Income (Expenses) | 1.59 | - | - | - | - |
Pretax Income | -69.77 | -86.4 | -13.87 | -9.15 | -13.17 |
Net Income | -69.77 | -86.4 | -13.87 | -9.15 | -13.17 |
Net Income to Common | -69.77 | -86.4 | -13.87 | -9.15 | -13.17 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 2,165 | 1,845 | 1,502 | 1,154 | 973 |
Shares Outstanding (Diluted) | 2,165 | 1,845 | 1,502 | 1,154 | 973 |
Shares Change | 17.34% | 22.87% | 30.12% | 18.58% | 0.02% |
EPS (Basic) | -0.03 | -0.05 | -0.01 | -0.01 | -0.01 |
EPS (Diluted) | -0.03 | -0.05 | -0.01 | -0.01 | -0.01 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -64.6 | -78.87 | -8.24 | -12.08 | -11.19 |
Free Cash Flow Per Share | -0.03 | -0.04 | -0.01 | -0.01 | -0.01 |
Gross Margin | 57.55% | 34.85% | -76.48% | -51.83% | -273.62% |
Operating Margin | -205.05% | -1432.24% | -676.11% | -241.93% | -478.66% |
Profit Margin | -206.41% | -1492.37% | -670.20% | -242.66% | -478.10% |
Free Cash Flow Margin | -191.10% | -1362.39% | -398.17% | -320.27% | -406.24% |
EBITDA | -66.99 | -80.65 | -13.92 | -9.11 | -13.17 |
EBITDA Margin | -198.20% | - | - | -241.38% | - |
D&A For EBITDA | 2.32 | 2.26 | 0.07 | 0.02 | 0.02 |
EBIT | -69.31 | -82.91 | -13.99 | -9.13 | -13.19 |
EBIT Margin | -205.05% | - | - | -241.93% | - |
Revenue as Reported | - | - | - | - | 2.79 |